Company Overview: ESPR

Upcoming Projects (ESPR)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ESPR)

A Second Opinion: Reviewing the recent label expansion of Esperion Therapeutics Nexletol and Nexlizet for the reduction of cardiovascular risk
Ticker: ESPR
Executed On: Apr 04, 2024 at 02:00 PM EDT
Reviewing the recent label expansion of Esperion Therapeutics Nexletol and Nexlizet for the reduction of cardiovascular risk
Ticker: ESPR
Executed On: Mar 28, 2024 at 03:00 PM EDT
A 3rd View: A discussion of Nexletol (Bempedoic acid) and CLEAR Cardiovascular Outcome Trial ahead of detailed data at ACC
Ticker: ESPR
Executed On: Feb 16, 2023 at 04:00 PM EST
Another View: A discussion of Nexletol (Bempedoic acid) and CLEAR Cardiovascular Outcome Trial ahead of detailed data at ACC
Ticker: ESPR
Executed On: Feb 06, 2023 at 12:15 PM EST
A discussion of Nexletol (Bempedoic acid) and CLEAR Cardiovascular Outcome Trial ahead of detailed data at ACC
Ticker: ESPR
Executed On: Feb 03, 2023 at 10:30 AM EST
Two Week Delay: NEXLETOL (bempedoic acid) Survey
Ticker: ESPR
Executed On: Nov 21, 2022 at 04:18 PM EST
A Second Look: Digging into the use of Esperion's NEXLETOL (bempedoic acid) in atherosclerotic cardiovascular disease (ASCVD)
Ticker: ESPR
Executed On: Sep 26, 2022 at 09:00 AM EDT
Digging into the use of Esperion's NEXLETOL (bempedoic acid) in atherosclerotic cardiovascular disease (ASCVD)
Ticker: ESPR
Executed On: Sep 21, 2022 at 05:30 PM EDT

Expired Projects (ESPR)

Discussing Esperion's Nexletol for treating heterozygous familial hypercholesterolemia, following March 4 results.
Ticker: ESPR
Execute By: Apr 30, 2023

Upcoming & Overdue Catalysts (ESPR)

Following CLEAR CVOT, Esperion Therapeutics (ESPR) to submit New Drug Application to FDA for reduction of risk of cardiovascular disease, MAA to EMA, by 2022
Ticker: ESPR
Future Window: Jan 01, 2022 - Dec 31, 2022
Overdue

Occurred Catalysts (ESPR)

Esperion (ESPR) Announces FDA Approval of NEXLETOL (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Ticker: ESPR
Occurred on: Feb 21, 2020
Esperion Therapeutics set to launch global cardiovascular outcomes trial (CVOT) on bempedoic acid on major cardiovascular events for high-risk cardiovascular disease (CVD) patients by first half of 2019
Ticker: ESPR
Occurred on: Mar 18, 2019
In the first half of 2019., Esperion Therapeutics (ESPR) plans to submit a New Drug Application (NDA) for bempedoic acid aimed at lowering low density lipoprotein cholesterol (LDL-C)
Ticker: ESPR
Occurred on: Feb 28, 2019
Top-Line Results Released from Esperion's ($ESPR) Final Pivotal Phase 3 Study of Bempedoic Acid
Ticker: ESPR
Occurred on: Oct 28, 2018
Top-line results from Esperion's (ESPR) pivotal Phase 3 study (1002FDC-053) of the bempedoic acid / ezetimibe combination pill in ASCVD and/or HeFH patients on maximally tolerated statin background therapy expected in August 2018
Ticker: ESPR
Occurred on: Aug 27, 2018
Top-line results from Esperion's (ESPR) Phase 3 study 1 (1002-040) of bempedoic acid in ASCVD who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statins expected in Sept 2018
Ticker: ESPR
Occurred on: Aug 25, 2018
Top-line results from Esperion's (ESPR) pivotal Phase 3 Study 1 (1002-040) of bempedoic acid in ASCVD and/or heterozygous familial hypercholesterolemia (HeFH) patients on maximally tolerated statin background therapy expected in May 2018
Ticker: ESPR
Occurred on: May 02, 2018
Top-line results expected Esperion's (ESPR) Phase 2 study (1002-039) of bempedoic acid added-on to a once-monthly injectable PCSK9 inhibitor expected in March 2018
Ticker: ESPR
Occurred on: Mar 27, 2018
Esperion Therapeutics (ESPR) looking to release top-line data on Phase 3 lowering low density lipoprotein cholesterol LDL-C lower lowering efficacy studies on bempedoic acid by mid-2018
Ticker: ESPR
Occurred on: Mar 07, 2018
Top-line results of Phase 3 long-term safety and tolerability study ETC-1002-040 of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins expected in Q2 2018
Ticker: ESPR
Occurred on: Mar 07, 2018
Top-line results from Esperion's (ESPR) pivotal Phase 3 Study 3 (1002-046) of bempedoic acid in ASCVD patients on less than approved daily starting doses of statins (high CV risk patients considered statin intolerant) expected May 2018
Ticker: ESPR
Occurred on: Mar 03, 2018
MRK's CETP CV outcomes for hypercholesterolemia expected in Q1 2017
Tickers: MRK, AMGN, ESPR
Occurred on: Jun 27, 2017
FDA reviews Esperion (ESPR) Phase 3 trial of bempedoic acid for low density lipoprotein cholesterol (LDL-C) and announces it is satisfactory to support approval
Ticker: ESPR
Occurred on: Mar 20, 2017
FDA Confirms Design of Phase 3 Trial Evaluating Esperion's (ESPR) Bempedoic Acid for Lowering Low Density Lipoprotein Cholesterol (LDL-C)
Ticker: ESPR
Occurred on: Mar 20, 2017
Esperion (ESPR) to Announce Clinical Development and Regulatory Plans for Bempedoic Acid + Ezetimibe (BA+EZ) in H1 2017
Ticker: ESPR
Occurred on: Mar 07, 2017
Esperion plans to initiate the global pivotal Phase 3 CLEAR LDL-C lowering efficacy studies and the global CLEAR Outcomes trial in Q4 2016
Ticker: ESPR
Occurred on: Jan 09, 2017
Esperion plans to announce top-line results from the Phase 1 (1002-037) and Phase 2 (1002-035) clinical studies of bempedoic acid and high-dose statins
Ticker: ESPR
Occurred on: Oct 13, 2016
Esperion Therapeutics (ESPR) Announces Phase 2 Data Evaluating Bempedoic Acid Added to Atorvastatin in Hypercholesterolemia
Tickers: ESPR, PFE
Occurred on: Oct 13, 2016
Esperion initiates global Phase 3 long-term safety and tolerability study ETC-1002-040 of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Ticker: ESPR
Occurred on: Jan 13, 2016

Strategic Initiatives (ESPR)

Don’t see a strategic initiative related to the company you care about? Create your own!

ESPR Overview